Immunome Set to Release Q4 2025 Earnings on March 18

Immunome (NASDAQ: IMNM) is scheduled to announce its financial results for the fourth quarter of 2025 before the market opens on March 18, 2026. Expectations are for the company to report earnings of ($0.64) per share, along with projected revenue of $0.785 million for the quarter.

Investors can access the latest details regarding the earnings call, set for March 3, 2026 at 15:00 ET, on the company’s Q4 2025 earnings summary page. This upcoming announcement follows Immunome’s previous quarterly report on March 3, 2025, where the company reported a loss of ($0.75) per share, falling short of analysts’ consensus estimates of ($0.65) by ($0.10).

The company has struggled financially, evidenced by a negative return on equity of 57.61% and a staggering negative net margin of 1,687.08%. Analysts project that Immunome will post a loss of ($2) per share for the current fiscal year and ($3) per share for the next fiscal year.

Current Market Performance and Institutional Investment

As of Monday, Immunome’s stock opened at $20.36. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -8.41, and a beta of 2.12. Its 50-day moving average stands at $22.73, while the two-hundred day moving average is $18.18. Over the past year, Immunome’s stock has fluctuated significantly, with a 12-month low of $5.15 and a high of $27.65.

Recent trading activity has seen notable changes in institutional holdings. T. Rowe Price Investment Management Inc. increased its stake in Immunome by 59.4%, acquiring an additional 5,003,824 shares, bringing its total to 13,421,987 shares valued at approximately $288.3 million. Similarly, Invesco Ltd. raised its position by 382.1%, acquiring 214,049 shares for a total worth of $5.8 million.

Other institutional investors such as Virtus Investment Advisers LLC and Wellington Management Group LLP have also increased their holdings significantly, indicating growing interest in the company. Currently, institutional investors and hedge funds own approximately 44.58% of Immunome’s stock.

Analysts’ Ratings and Price Targets

Equities research analysts have offered varying perspectives on Immunome’s stock. Evercore recently raised its price target from $18.00 to $40.00, rating the stock as “outperform.” In contrast, Wall Street Zen downgraded Immunome from “hold” to “sell.”

Other analysts such as Lake Street Capital and Craig Hallum have set price targets of $32.00 and $36.00, respectively, maintaining a “buy” rating. Overall, ten analysts have rated Immunome as “buy,” while one has assigned a “sell” rating. According to MarketBeat, the stock currently holds an average rating of “Moderate Buy” with an average price target of $33.45.

About Immunome: Immunome, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative antibody-based therapies for oncology and infectious diseases. The company utilizes a proprietary platform that identifies fully human monoclonal antibodies from the natural B-cell repertoire of patients with active diseases. Their lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Investors and stakeholders can stay updated on Immunome’s latest developments by subscribing to the daily news summary from MarketBeat.